Market revenue in 2023 | USD 103.5 million |
Market revenue in 2030 | USD 171.4 million |
Growth rate | 7.5% (CAGR from 2023 to 2030) |
Largest segment | Biomarker services |
Fastest growing segment | Genetic Services |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Genetic Services, Biomarker Services, Microbiology Services, Anatomic Pathology/Histology, Specimen Management & Storage, Special Chemistry Services |
Key market players worldwide | LabConnect, Eurofins Scientific SE, A. P. Moller Maersk A/S ADR, ACM Global, Cerba Research, Synevo Central Labs, Versiti, Cenetron, Ampersand Capital Partners, Pacific Biomarkers, Cirion |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to central lab market will help companies and investors design strategic landscapes.
Biomarker services was the largest segment with a revenue share of 38.36% in 2023. Horizon Databook has segmented the Canada central lab market based on genetic services, biomarker services, microbiology services, anatomic pathology/histology, specimen management & storage, special chemistry services covering the revenue growth of each sub-segment from 2018 to 2030.
The Canadian central lab market is expected to witness significant growth over the forecast period due to strong funding support from government initiatives, advanced healthcare infrastructure, and high-quality clinical research prospects.
The country accounts for 4% of the global number of clinical trials and ranks fourth in terms of the number of trial sites worldwide. Canada hosts a publicly funded healthcare system and consists of several health charities for clinical trials in cancer, cardiovascular, and other disease areas.
These factors enhance the clinical trial prospects for Canada. Furthermore, clinical trials in the country are supported by the Canadian government, which, through its Strategic Innovation Fund (SIF), provides funding opportunities to drive clinical development.
Horizon Databook provides a detailed overview of country-level data and insights on the Canada central lab market , including forecasts for subscribers. This country databook contains high-level insights into Canada central lab market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account